{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:09:39Z","timestamp":1761523779167,"version":"3.37.3"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2019,5,17]],"date-time":"2019-05-17T00:00:00Z","timestamp":1558051200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,5,17]],"date-time":"2019-05-17T00:00:00Z","timestamp":1558051200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1007\/s00520-019-04863-5","type":"journal-article","created":{"date-parts":[[2019,5,17]],"date-time":"2019-05-17T07:05:28Z","timestamp":1558076728000},"page":"3179-3182","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Oxaliplatin-desensitization procedure is safe and feasible in an outpatient cancer unit in France"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2117-4750","authenticated-orcid":false,"given":"Damien","family":"Botsen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elise","family":"Lepoix","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camille","family":"Mazza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathilde","family":"Brasseur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Grange","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Slimano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Bouch\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,5,17]]},"reference":[{"issue":"23","key":"4863_CR1","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1056\/NEJMoa032709","volume":"350","author":"T Andr\u00e9","year":"2004","unstructured":"Andr\u00e9 T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J, Tabah-Fisch I, de Gramont A (2004) Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350(23):2343\u20132351","journal-title":"N Engl J Med"},{"issue":"2","key":"4863_CR2","doi-asserted-by":"publisher","first-page":"106","DOI":"10.3816\/CCC.2009.n.017","volume":"8","author":"EI Syrigou","year":"2009","unstructured":"Syrigou EI, Karapanagiotou EM, Alamara CV, Boura PG, Saif MW, Syrigos KN (2009) Hypersensitivity reactions to oxaliplatin: a retrospective study and the development of a desensitization protocol. Clin Colorectal Cancer 8(2):106\u2013109","journal-title":"Clin Colorectal Cancer"},{"issue":"3","key":"4863_CR3","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/sj.bjc.6601155","volume":"89","author":"G Brandi","year":"2003","unstructured":"Brandi G, Pantaleo MA, Galli C, Falcone A, Antonuzzo A, Mordenti P, Di Marco MC, Biasco G (2003) Hypersensitivity reactions related to oxaliplatin (OHP). Br J Cancer 89(3):477\u2013481","journal-title":"Br J Cancer"},{"issue":"1","key":"4863_CR4","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.jaip.2013.11.007","volume":"2","author":"DI Hong","year":"2014","unstructured":"Hong DI, Dioun AF (2014) Indications, protocols, and outcomes of drug desensitizations for chemotherapy and monoclonal antibodies in adults and children. J Allergy Clin Immunol Pract 2(1):13\u201319 quiz 20","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"4863_CR5","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.jaci.2008.02.044","volume":"122","author":"MC Castells","year":"2008","unstructured":"Castells MC, Tennant NM, Sloane DE, Hsu FI, Barrett NA, Hong DI, Laidlaw TM, Legere HJ, Nallamshetty SN, Palis RI, Rao JJ, Berlin ST, Campos SM, Matulonis UA (2008) Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. J Allergy Clin Immunol 122(3):574\u2013580","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"4863_CR6","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jaip.2013.08.011","volume":"2","author":"JT Wong","year":"2014","unstructured":"Wong JT, Ling M, Patil S, Banerji A, Long A (2014) Oxaliplatin hypersensitivity: evaluation, implications of skin testing, and desensitization. J Allergy Clin Immunol Pract 2(1):40\u201345","journal-title":"J Allergy Clin Immunol Pract"},{"unstructured":"National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Protocol Development (2010) | CTEP","key":"4863_CR7"},{"issue":"7","key":"4863_CR8","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1111\/all.12105","volume":"68","author":"R Madrigal-Burgaleta","year":"2013","unstructured":"Madrigal-Burgaleta R, Berges-Gimeno MP, Angel-Pereira D, Ferreiro-Monteagudo R, Guillen-Ponce C, Pueyo C, Gomez de Salazar E, Alvarez-Cuesta E (2013) Hypersensitivity and desensitization to antineoplastic agents: outcomes of 189 procedures with a new short protocol and novel diagnostic tools assessment. Allergy 68(7):853\u2013861","journal-title":"Allergy"},{"issue":"4_suppl","key":"4863_CR9","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1200\/JCO.2018.36.4_suppl.610","volume":"36","author":"F Le Roy","year":"2018","unstructured":"Le Roy F, Rigault E, Regnault D, Hubert N, Burtin P, Hollebecque A, Malka D, Boige V, Ducreux M (2018) Oxaliplatin desensitization after hypersensitivity reaction: a single-center experience on more than 300 procedures. J Clin Oncol 36(4_suppl):610\u2013610","journal-title":"J Clin Oncol"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-019-04863-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-019-04863-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-019-04863-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T23:41:32Z","timestamp":1589586092000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-019-04863-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,17]]},"references-count":9,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["4863"],"URL":"https:\/\/doi.org\/10.1007\/s00520-019-04863-5","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"type":"print","value":"0941-4355"},{"type":"electronic","value":"1433-7339"}],"subject":[],"published":{"date-parts":[[2019,5,17]]},"assertion":[{"value":"26 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"For this type of study format consent is not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}},{"value":"For this type of study format consent is not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Damien Botsen reports personal fees from Pierre Fabre and non-financial support from GlaxoSmithKline, Novartis, Chugai, and Amgen outside the submitted work.Camille Mazza reports personal fees from Pierre Fabre outside the submitted work.Mathilde Brasseur reports personal fees from Bayer and non-financial support from Pierre Fabre, Novartis, Amgen, Roche, and AbbVie outside the submitted work.Olivier Bouche reports grants from Roche, personal fees from Roche, grants from Pierre Fabre, personal fees from Pierre Fabre, personal fees from Amgen, personal fees from Bayer, personal fees from Lilly, personal fees from Merck, personal fees from Novartis, outside the submitted work.Elise Lepoix, Florian Slimano, and Anne Grange: none.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}